Abstract: Unspecified
BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment
The serum levels of B cell-activating factor of the TNF family (BAFF), also called B lymphocyte stimulator (BLyS), have been shown to be increased in patients with several inflammatory rheumatic diseases [1] [2] [3] . Although B cells are not commonly associated with the pathogenesis of ankylosing spondylitis (AS), some findings corroborate their potential involvement. Dense infiltrations of B cells were found in the spine of patients with active inflammation [4] . Moreover, anti-tumour necrosis factor treatment (aTNF)-naïve patients showed a good treatment response to B cell depletion with rituximab [5] . As BAFF is a potent B cell survival and maturation factor, we analyzed BAFF levels in AS patients before and after As a conclusion, BAFF is not elevated in AS patients, in contrast to other chronic inflammatory rheumatic diseases [2, 3] . Therapeutic inhibition of the BAFF pathway with belimumab [6] or atacicept [7] is therefore not warranted in AS. As opposed to patients with rheumatoid arthritis showing a decrease in BAFF levels following a good response to TNF inhibition [8] , we observed a slight increase in BAFF after aTNF. Whether this finding might explain the fact that B cell depletion with rituximab is not very effective following aTNF in AS remains unclear. non-responders. Serum samples were collected at baseline (BL) and 3 months treatment initiation.
